$63.37 Million in Sales Expected for GW Pharmaceuticals PLC- (GWPH) This Quarter

Wall Street brokerages expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to announce $63.37 million in sales for the current quarter, according to Zacks. Six analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings, with the lowest sales estimate coming in at $40.62 million and the highest estimate coming in at $149.90 million. GW Pharmaceuticals PLC- reported sales of $3.46 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 1,731.5%. The firm is expected to issue its next earnings report on Tuesday, August 6th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full-year sales of $218.50 million for the current financial year, with estimates ranging from $169.27 million to $303.80 million. For the next financial year, analysts forecast that the company will post sales of $542.45 million, with estimates ranging from $360.07 million to $879.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The business had revenue of $39.20 million during the quarter, compared to the consensus estimate of $12.32 million. During the same quarter in the prior year, the firm earned ($3.12) EPS. The company’s revenue for the quarter was up 1189.5% compared to the same quarter last year.

A number of equities research analysts recently weighed in on GWPH shares. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, February 6th. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Guggenheim started coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, February 22nd. They set a “buy” rating and a $178.00 price objective for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $185.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $193.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. GW Pharmaceuticals PLC- currently has an average rating of “Buy” and an average price target of $205.40.

Shares of NASDAQ:GWPH traded down $5.55 during trading on Thursday, reaching $175.05. 410,018 shares of the company’s stock traded hands, compared to its average volume of 470,429. The company has a quick ratio of 7.19, a current ratio of 7.81 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a 12 month low of $90.14 and a 12 month high of $196.00. The company has a market cap of $5.28 billion, a PE ratio of -16.58 and a beta of 2.75.

In other GW Pharmaceuticals PLC- news, CEO Justin D. Gover sold 11,112 shares of the company’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $12.45, for a total value of $138,344.40. Following the completion of the transaction, the chief executive officer now owns 392,885 shares in the company, valued at approximately $4,891,418.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Christopher J. Tovey sold 200,736 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $16.14, for a total transaction of $3,239,879.04. Following the completion of the transaction, the chief operating officer now owns 203,239 shares of the company’s stock, valued at approximately $3,280,277.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,005,064 shares of company stock valued at $44,644,134. 5.50% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. Canada Pension Plan Investment Board lifted its stake in shares of GW Pharmaceuticals PLC- by 327.3% in the 4th quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock worth $114,424,000 after acquiring an additional 900,000 shares during the period. Jennison Associates LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 39.2% in the 4th quarter. Jennison Associates LLC now owns 515,281 shares of the biopharmaceutical company’s stock worth $50,183,000 after acquiring an additional 145,227 shares during the period. Federated Investors Inc. PA lifted its stake in shares of GW Pharmaceuticals PLC- by 23.5% in the 1st quarter. Federated Investors Inc. PA now owns 417,750 shares of the biopharmaceutical company’s stock worth $70,420,000 after acquiring an additional 79,367 shares during the period. Victory Capital Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 80.4% in the 1st quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock worth $68,935,000 after acquiring an additional 182,210 shares during the period. Finally, Marshall Wace North America L.P. lifted its stake in shares of GW Pharmaceuticals PLC- by 1,564.3% in the 1st quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock worth $53,419,000 after acquiring an additional 297,858 shares during the period. 79.60% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Story: What is the price-sales ratio?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.